Adaptimmune Therapeutics PLC banner

Adaptimmune Therapeutics PLC
NASDAQ:ADAP

Watchlist Manager
Adaptimmune Therapeutics PLC Logo
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Watchlist
Price: 0.036 USD -12.2% Market Closed
Market Cap: $9.5m

Wall St Price Targets

ADAP Price Targets Summary
Adaptimmune Therapeutics PLC

There are no price targets for ADAP.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Adaptimmune Therapeutics PLC Competitors:
Price Targets
TRIN
Trinity Capital Inc
3% Upside
LAND
Gladstone Land Corp
2% Upside
TTD
Trade Desk Inc
10% Upside

Revenue
Forecast

68% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
68% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 11 years, the compound annual growth rate for Revenue has been 68%. The projected CAGR for the next 4 years is 9%.

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ADAP's stock price target?
Not Available

ADAP does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Adaptimmune Therapeutics PLC?
Projected CAGR
9%

Over the last 11 years, the compound annual growth rate for Revenue has been 68%. The projected CAGR for the next 4 years is 9%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett